Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.45 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | VNN1 | O95497 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7925187 | 1.00 | CES2 (0.49) | CES2MAOBTBXAS1LMNASRD5A2 | |
| SCHEMBL7535000 | 0.79 | MTNR1A (0.47) | CES2TBXAS1ALDH1A1 | |
| SCHEMBL7917569 | 0.78 | GSK3B (0.53) | CES2MAOBSRD5A2 | |
| SCHEMBL7928744 | 0.77 | TBXAS1 (0.42) | CES2MAOBTBXAS1LMNASRD5A2 | |
| SCHEMBL7928743 | 0.77 | TBXAS1 (0.42) | CES2MAOBTBXAS1LMNASRD5A2 | |
| SCHEMBL7923784 | 0.76 | SMN1; SMN2 (0.45) | KCNK3MEN1KMT2APOLB | |
| SCHEMBL7923651 | 0.76 | ERCC5 (0.42) | MAOBKCNK3MEN1KMT2A | |
| SCHEMBL7923653 | 0.76 | ERCC5 (0.42) | MAOBKCNK3MEN1KMT2A | |
| SCHEMBL7923787 | 0.76 | SMN1; SMN2 (0.45) | KCNK3MEN1KMT2APOLB | |
| SCHEMBL11379914 | 0.75 | MAOB (0.58) | CES2MAOBLMNASRD5A2KCNK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6174898-B1 | TREATING FILARIAE IN LYMPHATIC SYSTEM BY ADMINISTERING N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND ESTERS IN WHICH A SUBSTITUTED ALKYL CHAIN FORMS PART OF N-SUBSTITUENT AND SALTS | NOVO NORDISK A/S (DK) | 2001-01-16 | — | — | US | disclosed |
| EP-0858339-A1 | A METHOD OF TREATING FILARIAE | NOVO NORDISK A/S (DK) | 1998-08-19 | — | — | EP | disclosed |
| EP-0502031-B1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND A PHARMACEUTICAL COMPOSITION | NOVO NORDISK AS (DK) | 1997-08-20 | — | — | EP | disclosed |
| WO-1997017073-A1 | A METHOD OF TREATING FILARIAE | NOVO NORDISK A/S (DK) | 1997-05-15 | — | — | WO | disclosed |
| US-5198451-A | Treatment of epilepsy, inhibitors of gamma-aminobutyric acid uptake from synaptic cleft | NOVO NORDISK A/S (DK) | 1993-03-30 | — | — | US | disclosed |
| EP-0502031-A1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND A PHARMACEUTICAL COMPOSITION. | NOVO NORDISK AS (DK) | 1992-09-09 | — | — | EP | disclosed |
| WO-1991007389-A1 | N-SUBSTITUTED AZAHETEROCYCLIC CARBOXYLIC ACIDS AND A PHARMACEUTICAL COMPOSITION | NOVO NORDISK A/S (DK) | 1991-05-30 | — | — | WO | disclosed |